Archive: 25/08/2017

More evidence evolocumab exceeds cost-effectiveness

(HealthDay)—At its current price, the addition of evolocumab to standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published ...

Aug 25, 2017
popularity0 comments 0